# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹8,646 Cr** consolidated (+8.4%) * Gross Margin: 59.7% (₹5,165 Cr gross contribution) * EBITDA: ₹1,773 Cr (20.5% margin, +9% YoY) * **Net Profit:** **₹910 Cr** (after one-time cost of ₹65 Cr) * **Cash Flow:** **$118 Mn** net inflow; **$251 Mn** outflow for acquisition (as of Mar-25) ## B. Revenue Growth * **Broad-Based Expansion:** Revenue growth driven by strong European performance, stable U.S. operations, and contributions from growth markets. ## C. Gross Margin * **Margin Resilience:** Gross margin reached 7%, supported by favorable business mix and lower raw material costs, with quarterly performance marking one of the highest levels despite absence of high-margin Revlimid. * **Currency Neutrality:** Rupee depreciation has minimal net impact on gross margins due to offsetting translation effects on revenues and costs. ## D. EBITDA & Profit * **Underlying Profitability Strength:** Ex-g-Revlimid, sales, gross profit, and EBITDA grew at strong double-digit rates, reflecting operating leverage and reduced exposure to transient products. * **Cost Absorption:** Market-wide price declines—particularly in Amoxicillin and 6APA—were absorbed within EBITDA, with Pen-G production now at breakeven or slight profit. * **Tax Headwind:** Elevated tax rate persists due to conservative accounting—no deferred tax assets recognized for losses at CuraTeQ and Lyfius despite R&D and ramp-up costs. * **Expense Inflation:** Other expenses rose to **₹2,000 Cr** from prior levels due to currency translation impacts on dollar- and euro-denominated costs. ## E. Cash Flow * **Strategic Deployment:** Strong operating cash flow generated **$118 Mn** inflow, partially offset by **$251 Mn** spent on a domestic pharma acquisition**, signaling continued inorganic growth focus. * **Currency Impact Acknowledged:** Management confirms recent rupee depreciation is already reflected in P&L via average exchange rate translation; no additional lag effect expected. --- # 2. Product & Segment Performance ## A. Key Figures * **US Formulations Revenue:** ₹7,683 Cr (+10%) · **89%** of total revenue * **Europe Revenue:** ₹2,703 Cr (+27%) · €261 Mn * **API Revenue:** ₹963 Cr (**11%** of total) * **Growth Markets Revenue:** ₹865 Cr (USD 97 Mn) * **US Injectables Growth:** +17% YoY * **R&D Expenditure:** ₹409 Cr (**5%** of revenue) * **ARV Formulations Revenue:** ₹376 Cr (+22%) ## B. US Formulations * **Core Growth Engine:** US formulations remain the dominant revenue driver with solid double-digit volume growth, recent launches, and a stable oral solids base supporting resilience. * **Pipeline & Portfolio Momentum:** Growth outlook underpinned by scalable initiatives in **complex generics** (dermal, oncology, respiratory) and incremental gains from portfolio acquisitions. * **Future Revenue Inflection:** **Dayton facility** now in commercial manufacturing, with material contributions expected from FY27; **Lannett acquisition** poised to enhance scale pending approvals. * **OTC Generics Emergence:** US OTC segment has become a **fast-growing vertical**, with strong volume momentum expected through 2025–2026 despite lack of disclosed figures. * **Launch Cadence:** **Nine US product launches** in Q4; management targets similar pace over next 12 months, though subject to regulatory timing. ## C. Europe Growth * **Outperformance & Scale:** Europe delivered robust top-line expansion, outpacing market growth with **low double-digit constant currency gains** and strong execution in France, Germany, Portugal, and the Netherlands. * **Path to €1B Revenue:** Current trajectory positions Europe to **exceed €1 billion in annual revenue by end-FY26**, supported by product basket expansion and reliable supply. * **New Market Penetration:** Secured first tender in **Mexico**, marking strategic entry and early success in a new geography. ## D. API & Biosimilars * **Margin Improvement Pathway:** API segment sees **declining production costs** and rising internal manufacturing, paving way for gross margin expansion despite flat revenue. * **Biosimilar Commercialization Accelerates:** Transitioned to commercial phase with **Bevqolva (Bevacizumab)** launched in UK and **Dazublys (Trastuzumab)** in Baltics; **Dyrupeg** gains first approval in Canada after four EEA nods. * **R&D Focus:** Sustained investment at **5% of revenue** targets complex generics and specialty therapies, reinforcing long-term differentiation. ## E. Injectables * **Strong Operational Recovery:** US injectables achieved **17% YoY growth** on back of 9 launches and 7 approvals, with improved capacity utilization and supply reliability. * **Growth Resilience Amid Regulatory Overhang:** Double-digit growth expected to continue despite unresolved **FDA warning letter at Eugia**; other facilities compensating via ramp-up. * **Upside Potential:** Sales trajectory could materially improve post-resolution of FDA issues, indicating embedded optionality. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Pen-G Production Ramp:** **65–70%** utilization expected by Mar '26 (vs. **42%** avg in FY25) * **Annualized Output:** **9,000–10,000 MT** achieved as of January '26 * **Planned Production:** **10,000 tons** from Pen-G facility over next year, monetization from **Q1 FY27** * **Manufacturing Capacity:** **>6,000 crore units** current capacity, with ongoing expansion * OSD China Capacity: Scaling to 2 billion units/year, backed by 10 EU + 3 local approvals ## B. Pen-G Ramp-up * **Ahead-of-Expectations Profitability:** Pen-G facility has already reached **break-even** and is making a small positive earnings contribution, earlier than projected. * **Structural Margin Driver:** PEN-G, 6APA, and Amoxicillin integration enhances cost competitiveness via **in-house conversion at liquid level**, avoiding crystallization and delivering **cost savings**. * **Strong Momentum & Utilization:** Recent output runs at full annualized capacity, with **internal consumption of nearly all production**, signaling seamless integration into downstream operations. * **Future EBITDA Upside:** **Significantly improved EBITDA expected in FY27** driven by higher yields, increased volumes, and favorable pricing versus MIP benchmarks. ## C. Facility Progress * **Multi-Site Ramp-Up Underway:** Several key units—Lyfius, Qule, Auroactive, China, Dayton, Raleigh, Eugia Steriles—are in ramp-up, contributing to near-term EBITDA pressure but building long-term scale. * **Strategic Capacity Optimization:** AuroVaccines merger enables repurposing of underutilized biosimilar-era assets for future pipeline flexibility and operational efficiency. * **Capacity Expansion Supports Leverage:** Growing manufacturing footprint across geographies positions the company to meet rising demand and improve operating leverage. ## D. Biologics Expansion * **Biosimilars Strategy on Track:** Progress in biologics aligns with long-term growth goals, with commercial contributions expected from **FY28**. * **Vizag Injectables Pipeline Advancing:** Facility has filed **3 products**, with **10 more in pipeline** including a **key GLP-1 candidate**, leveraging **cartridge, PFS, and BFS** capabilities across **8 planned lines**. --- # 4. Supply & Sourcing Mix ## A. Key Figures * **In-house Sourcing for Europe:** **60%** from company-owned sites ## B. In-house Sourcing * **Localization Drive:** Strategic expansion of **in-house production** for single-use systems and critical consumables to mitigate supply chain risks highlighted during COVID disruptions. * **Vertical Integration Trend:** Ongoing shift from third-party to owned facilities supports supply security and operational control in Europe. ## C. China Operations * **Policy Tailwinds:** New Indian government import pricing mechanism for key APIs acts as a **significant positive catalyst** for domestic manufacturers. * **Margin Support:** Rising China-to-Europe supply flows enhance global cost efficiency and contribute to margin optimization. * **Growth Trajectory:** China supply recovery enabling quarter-on-quarter improvement, supported by new product launches and post-exclusivity opportunities. ## D. External Sales * **Market Re-entry:** Resumption of **6APA external sales** expected in Q1 due to favorable market pricing and adequate inventory levels. --- # 5. Regulatory & Compliance ## A. Key Figures * **MIP for 6-APA:** **$37/kg** (vs. implied $50/kg) * **SOP Update Timeline:** **1 week to 10 days** for FDA observations * **Response Deadline:** **15 working days** to USFDA ## B. FDA Observations * **Raleigh Facility Status:** Remains pending regulatory clearance, with full operational scalability confirmed upon approval. * **Eugia III Inspection Outcome:** Findings limited to procedural and technical issues, with **no production halt** or data integrity concerns—marked improvement from prior inspection. * **Regulatory Confidence:** Company expects timely resolution of observations, requiring only minor corrective actions. * **Inspection Uncertainty:** No USFDA inspections pre-scheduled; near-term plant inspection pipeline remains unpredictable. ## C. MIP Impact * **6-APA Pricing Trend:** Prices are rising despite current MIP of $37/kg, signaling potential disconnect with modeled assumptions; outdated pricing discouraged. * **Biopharma Shakti Potential:** Initiative seen as positive for sectoral growth, with upside in skill development, clinical infrastructure, and regulatory predictability. * **Workforce Gap:** Human resource capacity remains a key constraint; success hinges on effective execution of skill-building components. ## D. ANVISA Inspection * **Brazil Market Expansion:** GMP inspection by ANVISA scheduled for May, potentially enabling approval of **at least four products**. --- # 6. Risks & Regulatory Exposure ## A. FDA Inspection Risk * **Procedural FDA Matter:** Eugia facility’s FDA observation is procedural; management is cautiously optimistic about resolution within timeline, though clearance remains subject to FDA decision. * **Unannounced Audit Risk:** USFDA conducts unannounced inspections, creating uncertainty around timing and facility prioritization for future audits. * **Strategic Regulatory Push:** Policy shift supports domestic API/KSM manufacturing, reducing supply chain risks and advancing India’s self-reliance in antibiotics. * **Capability Gap Challenge:** Building local clinical development expertise to meet FDA/EMA standards for complex biologics and biosimilars remains a key hurdle. ## B. Pricing Volatility * **6APA Price Recovery Expected:** International 6APA prices currently below cost due to predatory pricing; correction anticipated by end-March or April via MIP adjustments. * **MIP Based on Cost-Plus Framework:** Market Intervention Price likely reflects cost of production plus reasonable profitability, though specifics remain confidential. ## C. Integration Risk * **Lannett Deal Liability Protection:** Aurobindo bears no liability for Lannett’s pre-closing obligations, including settlement fines; acquisition price remains fixed. * **FTC Review Ongoing:** Active engagement with FTC on Lannett transaction; portfolio overlap under review, but no timeline or quantitative overlap disclosed. * **Synergy Outlook:** Pending FTC approval, Lannett acquisition is expected to generate synergies and enhance business performance. --- # 7. Guidance & Outlook ## A. Key Figures * **Net CapEx:** **$79 Mn** (Q) * **PLI Incentive:** **₹240 Cr** per 10,000 MT (disbursed proportionally) * **TheraNym CapEx:** **$120–130 Mn** (7 quarters, 2 products) * **Future Biologics CapEx:** **$80–120 Mn** (next 2 years, mostly FY27) * **CapEx Outlook:** **$150–200 Mn** (ex-biologics, FY27 estimate) ## B. Margin Trajectory * **FY26 Margin Target Intact:** Confidence maintained in achieving **20–21%+ EBITDA margins** on execution rigor and operational discipline. * **Margin Inflection Ahead:** Full benefit from Pen-G facility expected from **April FY27**, following inventory drawdown, enabling higher-margin production and external sales. * **Tax Rate Normalization Path:** Effective tax rate to gradually rise toward **25% long-term**, post-utilization of tax credits, aligning with Lyfius/Qule precedent. * **Near-Term Margin Stability:** Overall margins expected to be **broadly stable vs. current year**, with slight improvement potential on stronger financials. ## C. Launch Pipeline * **First-to-Market Catalyst:** Generic **Pomalidomide (Pomalyst)** launch confirmed **this quarter**, positioning for early-mover advantage. * **Biosimilar Filing Wave:** **Omalizumab and Denosumab** filings expected in **Europe and US by June/July**, enhancing commercial readiness and freeing capacity. * **2029 Biotech Inflection:** Biotech segment poised for step-up, driven by **four approved biosimilars** and **2–3 near-filing candidates**, with global rollout planned across EEA, LATAM, and Canada. ## D. CapEx Plan * **Capital Discipline Confirmed:** No major greenfield projects beyond TheraNym; M&A only at **strategic fit and right valuation**. * **PLI Payout Imminent:** With production near **9,000–10,000 MT**, full **₹240 Cr PLI incentive** expected in FY27, contingent on sustained output. * **Buyback Under Review:** Tax-efficient buyback option being evaluated post-April 1, considering **current share price** and promoter/non-promoter implications. * **Deal Closure in Sight:** TheraNym transaction expected to close in **Q1 FY27**, with due diligence clean and no adverse findings.